Literature DB >> 15555885

Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study.

Wendy J Munckhof1, Sharon L Kleinschmidt, John D Turnidge.   

Abstract

This study compares in vitro antimicrobial resistance development between strains of Staphylococcus aureus including newly described community-acquired methicillin-resistant strains (CA-MRSA). High-level resistance developed in all strains of S. aureus after exposure to rifampicin and gentamicin and in some strains after fusidic acid exposure, independent of methicillin resistance phenotype. Resistance did not develop after exposure to clindamycin, cotrimoxazole, ciprofloxacin, linezolid, or vancomycin. These results have important implications for therapy of CA-MRSA infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555885     DOI: 10.1016/j.ijantimicag.2004.08.009

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.

Authors:  Hao-Chieh Chiu; Su-Lin Lee; Naval Kapuriya; Dasheng Wang; Yi-Ru Chen; Sung-Liang Yu; Samuel K Kulp; Lee-Jene Teng; Ching-Shih Chen
Journal:  Bioorg Med Chem       Date:  2012-06-15       Impact factor: 3.641

Review 2.  Epidemiology, clinical manifestations, and treatment options for skin and soft tissue infection caused by community-acquired methicillin-resistant Staphylococcus aureus.

Authors:  Jason E Farley
Journal:  J Am Acad Nurse Pract       Date:  2008-02

Review 3.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

4.  Once-daily gentamicin administration for community-associated methicillin resistant Staphylococcus aureus in an in vitro pharmacodynamic model: preliminary reports for the advantages for optimizing pharmacodynamic index.

Authors:  Sun Woo Kim; Dong-Gun Lee; Su-Mi Choi; Chulmin Park; Jae-Cheol Kwon; Si-Hyun Kim; Sun Hee Park; Jung-Hyun Choi; Jin-Hong Yoo; Wan-Shik Shin
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

5.  Community-acquired methicillin-resistant Staphylococcus aureus: the new face of an old foe?

Authors:  Edet E Udo
Journal:  Med Princ Pract       Date:  2013-09-13       Impact factor: 1.927

6.  Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus isolates.

Authors:  Qianxing Wu; Niloofar Sabokroo; Yujie Wang; Marzieh Hashemian; Somayeh Karamollahi; Ebrahim Kouhsari
Journal:  Antimicrob Resist Infect Control       Date:  2021-06-30       Impact factor: 4.887

7.  Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III.

Authors:  Hee-Chang Jang; Seung-Ji Kang; Su-Mi Choi; Kyung-Hwa Park; Jong-Hee Shin; Hyon E Choy; Sook-In Jung; Hong Bin Kim
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

8.  Efficacy of cotrimoxazole (Sulfamethoxazole-Trimethoprim) as a salvage therapy for the treatment of bone and joint infections (BJIs).

Authors:  Laurene Deconinck; Aurélien Dinh; Christophe Nich; Thomas Tritz; Morgan Matt; Olivia Senard; Simon Bessis; Thomas Bauer; Martin Rottman; Jérome Salomon; Frédérique Bouchand; Benjamin Davido
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.